Viridian Therapeutics, Inc./DE (VRDN) Revenue 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$70.8MFY2025 · since FY2016: $3.5M → $70.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $70.8M | +23359.9% |
| FY2024 | $302,000 | -3.8% |
| FY2023 | $314,000 | -82.3% |
| FY2022 | $1.8M | -40.2% |
| FY2021 | $3.0M | +182.2% |
| FY2020 | $1.1M | -76.5% |
| FY2019 | $4.5M | -46.8% |
| FY2018 | $8.4M | +109.5% |
| FY2017 | $4.0M | +15.1% |
| FY2016 | $3.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating incomeVRDN Operating marginVRDN Operating cash flowVRDN Free cash flowVRDN Capital expendituresVRDN Return on equityVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Total liabilitiesVRDN Shareholders’ equityVRDN overview →